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The clinical, electrophysiologic and pharmacologic ef-
fects of chronic lorcainide therapy in patients with re-
fractory ventricular tachycardia were evaluated using
programmed electrical stimulation. Twelvepatients with
recurrent refractory ventricular tachycardia and or-
ganic heart disease, 10 men and 2 women aged 41 to 76
years, with no evidence of prior high degree atrioven-
tricular or bifascicular block were studied. Programmed
electrical stimulation was performed in the control, drug-
free state and after chronic administration of lorcainide
(dose range 200 to 600 mg/day, duration 48 to 240hours,
mean 106 hours) in 11 patients. One patient developed
intolerable drug side effects and treatment was discon-
tinued after 36 hours. In the 11 other patients, there
was a significant increase in PR interval (187 ± 55 to
219 ± 56 ms; p < 0.02); QRS duration (107 ± 10 to
127 ± 23 ms; p < 0.001) and QTc interval (404 ± 49
to 482 ± 58 ms; p < 0.005), but no change in RR interval
Lorcainide is a class I antiarrhythmic drug currently under
investigation in the United States. Initial reports (1-4) of
its clinical efficacy in supraventricular and ventricular ar-
rhythmias have been encouraging. However, its clinical ef-
ficacy in patients with recurrent ventricular tachycardia is
being debated. Conflicting observations have been reported
(5,6) regarding its ability to suppress induction of ventricular
tachycardia during programmed electrical stimulation after
intravenous administration. Lorcainide forms an active me-
tabolite (nor-lorcainide), which accumulates after multiple
drug doses and may reach a steady state over several days.
This might imply that acute drug testing during programmed
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(872 ± 147 to 762 ± 126 ms; p > 0.2). The ventricular
effective refractory period increased from 234 ± 21 to
266 ± 15 ms (p < 0.02). During the control studies, 11
patients had inducible sustained ventricular tachy-
cardia. After chronic lorcainide therapy, four patients
showed suppression of sustained ventricular tachy-
cardia, while seven patients continued to have inducible
sustained ventricular tachycardia.
Long-term lorcainide therapy was continued in the
four responders. During a 2 to 12 month follow-up pe-
riod, two patients have remained arrhythmia-free, one
patient developed intolerable side effects requiring dis-
continuation of the drug and one patient with advanced
renal failure died. It is concluded that chronic lorcainide
therapy has significant electrocardiographic and elec-
trophysiologic effects, but has a limited role in the long-
term treatment of patients with refractory sustained ven-
tricular tachycardia.
electrical stimulation may not predict chronic drug efficacy;
however, chronic electrophysiologic and pharmacologic
studies assessing lorcainide's efficacy have not been per-
formed. We evaluated the clinical, electrophysiologic and
pharmacologic effects of chronic lorcainide therapy in re-
current refractory ventricular tachycardia associated with
organic heart disease using programmedelectrical stimulation.
Methods
Patient selection. Twelve patients (10 men and 2 women)
ranging in age from 41 to 76 years (mean 63) with recurrent
and refractory ventricular tachycardia were studied. Recur-
rent ventricular tachycardia was defined as three or more
documented episodes of ventricular tachycardia and sus-
tained tachycardia was defined as an arrhythmia of more
than 30 seconds' duration or requiring immediate pharma-
cologic or electrical termination for rapid hemodynamic de-
terioration in a shorter period of time. Before the study, all
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patients had undergone serial electrophysiologic studies with
acute and chronic drug testing with conventional agents .
Acute drug testing was performed with intravenous lido-
caine , procainamide and phenytoin , whereas chronic oral
drug testing was performed with quinidine and disopyr-
amide . The highest tolerated drug dose was administered in
each instance, and therapeutic drug concentrations were
documented at the time of electrophysiologic study.
Fai/ure to respond to a particular therapeutic agent was
defined as the occurrence of any of the following : I) rein-
duction of sustained ventricular tachycardia during electro-
physiologic study; 2) spontaneous episodes of sustained ven-
tricular tachycardia with documented therapeutic drug
concentrations; and 3) acceleration in rate or change in mor-
phologic features of spontaneous or induced ventricular
tachycardia.
All patients in this study had either failed to respond to
all conventional agents as defined , or were intolerant of
them . Recent acute myocardial injury was excluded in all
patients by electrocardiographic and serum enzyme studies .
The diagnosis of ventricular tachycardia was made using
standard electrocardiographic criteria and proven by intra-
cardiac recordings demonstrating absence of concordance
between His and ventricular electrograms with HV interval s
less than those in normal sinus rhythm (7). All patients also
underwent cardiac catheterization and angiographic studies.
Patients were excluded if they had significant hepatic dys-
function , high degree atrioventricular (AV) block or bifas-
cicular block .
Study design. Complete history, physical and labora-
tory examinations were performed for each patient in the
study . Antiarrhythmic therapy was discontinued for at least
five drug half-lives before control electrocardiographic and
electrophysiologic studies. After these studies, intravenous
or oral lorcainide, or both, was administered. When intra-
venous lorcainide was administered as a loading dose, a
dose of 200 mg was given at a rate not exceeding 10 mg/
min. In one patient in whom oral therap y could not be
instituted , intravenous lorcainide admini stration was con-
tinued up to a maximum of 600 mg/day in divided doses .
All other patients were started on oral lorcainide therapy
(200 to 400 mg/day in divided doses). Orallorcainide was
admini stered initially as 50 mg every 8 hours. The drug
dose was increased up to 100 mg every 6 hours , or until
cardiac monitoring demonstrated suppres sion of sponta-
neous sustained ventricular tachycardia for a 24 hour period .
Oral lorcainide was administered in II of 12 patients for a
minimal period of 48 hours and a maximal period of 240
hours (mean 106). In one patient , oral lorcainide therapy
had to be discontinued because of sleep disturbances after
36 hours of drug administration . This patient was excluded
from data analysis.
Electrophysiologic techniques. All patients underwent
study in the nonsedated postabsorptive state. The initial
study was performed in the absence of antiarrhythmic ther-
apy for a period of five drug half-lives before study. With
the use of standard venous and arterial catheterization tech-
niques, three to four multipolar electrode catheters were
placed in the right and left heart chambers. These were used
for atrial and ventricular pacing and continuous monitoring
of the His bundle electrogram. Additional electrode cath-
eters were utilized for pacing and recording from other right
and left ventricular sites . Femoral artery blood pressure was
monitored in all studies utilizing an indwelling arterial can-
nula. All patients received intravenous heparin for anticoa-
gulation after electrode catheter insertion. Intracardiac elec-
trograms were usually monitored at the right atrium, AV
junction at the His bundle location, right ventricle at the
apex, septum or outflow tract , and left ventricle at the apex,
septum or inferior or lateral wall. Three surface electrocar-
diographic leads (I, aVF , VI) were also recorded simulta-
neously with the intracardiac electrograms. The latter were
filtered at 40 to 500 Hz and displayed on a multichannel
display recorder (Electronics for Medicine VR 12). Data
were stored on FM tape and hard copy recordings were
obtained at paper speeds of 100 to 250 mm/s . Programmed
electrical stimulation was performed utilizing a custom-made
programmed stimulator (Bloom Associates, Ltd) that deliv-
ered rectangular pulses of I ms duration at twice diastolic
threshhold (0 .4 to 2 rnA).
The programmed electrical stimulation protocol used for
induction ofventricular tachycardia included: I) single pre-
mature atrial extrastimuli during sinus and atrial drive rhythms
at two or more drive cycle lengths; 2) rapid atrial pacing
with incremental rates until the Wenckebach phenomenon
was observed; 3) single premature ventricular extrastimuli
in sinus rhythm; 4) single and double premature ventricular
extrastimuli in ventricular drive rhythm at two or more drive
cycle lengths; 5) bursts of rapid ventricular pacing (15 sec-
onds' duration) at cycle lengths ranging from 400 to 250
ms or up to ventricular refractory periods ; and 6) triple and
quadruple premature ventricular extra stimuli during ven-
tricular drive rhythm .
Single premature stimuli (Sz) were introduced at coupling
intervals (StS z) 20 ms shorter than the drive cycle length
late in diastole and StS Zwas then progressively shortened
by 10 to 20 ms decrements to the point of ventricular re-
fractoriness. The effective refractory period of the right
ventricle (VERP) was defined as the longest S\SZ interval
that failed to elicit a ventricular response . It was determined
at two ventricular pacing cycle lengths (range 400 to 600
ms) for each patient. Mean values of the right ventricular
effective refractory period obtained at the two cycle lengths
were used for statistical analysis. Subsequent premature stimuli
(S3' S4' Ss) were then introduced starting with coupling
intervals (SZS3, S3S4 and S4SS) 50 ms longer than the shortest
S ISz interval, resulting in consistent capture at a constant
drive cycle length (400 ms). These intervals were then de-
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fective refractory period) were performed in II patients
completing the study using the Student's paired t test.
Table 1. Standard Electrocardiographic Intervals (mean ± I
standard deviation in ms) During the Control State and After
Chronic Lorcainide Therapy
Results
Patient characteristics. Ten of the 12 patients in this
study had coronary artery disease, and 2 had congestive
cardiomyopathy. Six patients were in New York Heart As-
sociation functional class II, three were in class III and three
in class IV. In the group with coronary artery disease, one
patient had two vessel disease and nine patients had triple
vessel disease. Left ventricular aneurysms were present in
four patients. Left ventricular ejection fraction ranged from
10 to 40% (mean 31 ± 10). Left ventricular end-diastolic
pressure ranged from 8 to 45 mm Hg (mean 22 ± II).
Spontaneous sustained ventricular tachycardia was docu-
mented in 10 patients, and nonsustained ventricular tachy-
cardia in 2 patients. The duration of ventricular tachycardia
in these patients ranged from I to 36 months. Ten patients
had had 5 to 25 episodes of sustained ventricular tachy-
cardia, ~nd nine patients had been resuscitated from one or
more cardiac arrests.
Electrocardiographic intervals. Table I shows the
changes in electrocardiographic intervals in individual pa-
tients after chronic lorcainide administration. There was a
significant increase in PR interval (187 ± 55 to 219 ± 56
ms; probability [p] < 0.02), QRS duration (107 ± 10 to
127 ± 12 ms; p < 0.001) and QTc interval (404 ± 49 to
482 ± 58 ms; p < 0.005), with no significant change in
RR interval (872 ± 147 versus 762 ± 126 ms; p > 0.2).
PR prolongation during treatment with lorcainide was noted
both in patients with a normal PR interval and in those with
significant first degree atrioventricular (AV) block. One pa-
tient had a markedly prolonged PR interval that showed
further prolongation on drug therapy. There was no pro-
gression to higher degree AV block in any patient during
lorcainide administration; however, one patient developed
excessive QTc prolongation requiring reduction of the lor-
cainide dose.
Electrophysiologic observations. Right ventricular ef-
fective refractory period could be measured in nine patients
before and after chronic lorcainide administration (Fig. 1).
creased by 10 ms until refractoriness was reached and the
next premature stimulus was added.
During programmed ventricular stimulation, stimulation
was initially performed at the right ventricular apex. If re-
producible induction of arrhythmia was not achieved, al-
ternate right ventricular sites were used and the entire stim-
ulation protocol was repeated. If this failed to induce the
arrhythmia, left ventricular stimulation from one or more
left ventricular stimulation sites was performed using the
same protocol. In this study, none of the patients needed
pharmacologic agents, isoproterenol, for example, to assist
in the induction of ventricular tachycardia. Stimulation pro-
tocols were continued until reproducible induction of sus-
tained ventricular tachycardia was achieved.
Follow-up programmed electrical stimulation was per-
formed on completion oforal lorcainide therapy. The entire
stimulation protocol for the control study was repeated. The
same pacing cycle lengths used in the control study were
used in the follow-up electrophysiologic study for deter-
minations of right ventricular effective refractory period.
Follow-up programmed electrical stimulation was per-
formed 4 to 6 hours after administration of the previous
lorcainide dose. Plasma samples were obtained during the
follow-up electrophysiologic study for determination of lor-
cainide and nor-lorcainide concentrations using previously
described methods (8).
Cardiac monitoring. Continuous 24 hour cardiac mon-
itoring (Physio Control CMS 600 telemetry unit) was per-
formed in all patients from time of entry into the study
protocol up to 48 to 72 hours after follow-up programmed
electrical stimulation during treatment with lorcainide. Re-
cordings were usually obtained during the rest state, but six
patients were ambulatory during oral lorcainide treatment.
Noninvasive evaluation. In patients noted to have
suppression of sustained ventricular tachycardia during car-
diac monitoring and follow-up programmed electrical stim-
ulation, a 24 hour ambulatory electrocardiogram and an
exercise test were performed. A 24 hour Holter tape was
recorded using the ICR series 7200 Holter recorder and
scanning system and was scanned manually. Qualitative and
semiquantitative analyses were performed for detection of
single, paired or multiform premature ventricular complexes
and ventricular tachycardia. A symptom-limited treadmill
test was performed using a modified Bruce protocol.
Clinical follow-up. Patients on chronic oral lorcainide
therapy were followed up in an outpatient arrhythmia clinic.
Periodic cardiac monitoring using repeat ambulatory
electrocardiographic recordings or transtelephonic trans-
mitters to monitor arrhythmia recurrence was employed.
Duration of follow-up has ranged from 2 to 12 months (mean
7).
Statistical analysis. Statistical comparisons of electro-
cardiographic intervals (RR, PR, QRS and QTc) and elec-
trophysiologic variables (for example, right ventricular ef-
Electrocardiographic
Interval
RR
PR
QRS
QTc
p = probability.
Control
872 ± 147
187 ± 55
107 ± 10
404 ± 49
Lorcainide
762 ± 126
219 ± 56
127 ± 12
482 ± 58
p Value
> 0.2
< 0.02
< 0.001
< 0.005
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had severe central nervous system side effects and withdrew
from the study,
Eleven patients underwent follow-up programmed elec-
trical stimulation after 48 to 240 hours (mean 106) of lor-
cainide therapy, Four patients had no inducible sustained
ventricular tachycardia, In one patient, there were no re-
petitive ventricular responses and in three patients, three to
five repetitive ventricular responses could be elicited, In
three patients, sustained ventricular tachycardia could be
induced with a stimulation protocol that was previously
ineffective (fewer extrastimuli or ventricular pacing at slower
cycle lengths), but the arrhythmia was significantly slower
(mean increase in arrhythmia cycle length 70 ms), In four
patients, there was no change from the control study in the
arrhythmia cycle length or induction pattern, In all patients
with inducible sustained ventricular tachycardia during fol-
low-up studies, the pattern of arrhythmia was identical to
that noted during control studies, There were no inducible
additional or "nonclinical' patterns of ventricular tachycardia,
Figure 3 shows the response to programmed electrical
stimulation during control and follow-up studies in one pa-
tient during lorcainide therapy, During the control study,
three right ventricular extrastimuli induced sustained ven-
tricular tachycardia with a right bundle branch block pattern
and a cycle length of 250 ms (Fig, 3, top panel). After
initiation of lorcainide therapy, threee extrastimuli induced
a maximum of five repetitive ventricular responses at a
slower rate (Fig, 3, lower panel),
Drug levels. Plasma lorcainide concentration was de-
termined in eight patients at the time of electrophysiologic
study and ranged from 100 to 799 ng/ml (mean 310 ± 166).
Simultaneous values for nor-lorcainide concentration ranged
from 116 to 496 ng/ml (mean 256 ± 133) (Fig. 4), There
were no significant differences between drug levels in re-
sponders and nonresponders.
Clinical follow-up. Continuous 24 hour cardiac moni-
toring during hospitalization demonstrated no recurrence of
LORCAINIDECONTROl.
300
280
260
240
200
220
P<.02
Figure 1. Rightventricular(R.V,) effectiverefractory period(ms)
in the control state and after chronic lorcainide therapy in nine
patients, Mean value ± I standard deviation (vertical bars) are
shown adjoining individual values, p = probability,
1 _
The mean value increased significantly from 234 ± 21 to
266 ± 15 ms (p < 0,02),
During the control period ofprogrammed electrical stim-
ulation all 12 patients had inducible sustained ventricular
tachycardia with a configuration similar to that of sponta-
neous arrhythmia (Fig, 2), The cycle length of induced
ventricular tachycardia ranged from 190 to 480 ms (mean
318) and showed a right bundle branch block pattern in nine
patients and a left bundle branch block pattern in three
patients, After initiation of lorcainide therapy, one patient
SUSTAINED NONSUSTAINED
SPONTANEOIlS...YI
INDUCED VI
CONTROL (C) EPS
10
12
2
LORCAINIDE EPS 7
»<;
CLINICAL VT ADDITIONAL VT
7 0
~
3 4
SLOWER THAN NO CHANGE
C EPS FRON C EPS
INDUCTION
FACILITATED
3 (3-4 BEATS) 1 Figure 2. Response to programmed electricalstim-
ulationduringcontrol(C)electrophysiologic studies
(EPS)and after chronic lorcainideadministration in
the 12 study patients, VT "" ventricular tachycardia.
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spontaneous ventriculartachycardiain the four patients who
showed suppression of sustained ventricular tachycardia in-
ductionduring follow-up programmed electrical stimulation
studies. Two of the four patients were able to complete a
treadmill exercise test and had no arrhythmia noted during
the test. Lorcainide therapy was continued in these four
patients, but one patient was unable to continue treatment
after 7 days because of severe sleep disturbances. Periodic
Holter monitoring in the remaining patients showed single
ventricular premature depolarizations in one patient and
multiform and paired premature depolarizations in two pa-
tients. These patientshave remainedarrhythmia-free on lor-
cainide therapyduring a follow-upperiod of 2 to 12 months
(mean 7). One patient with advanced renal failure died after
2 months of treatment.
Nine of the 12 patients entering the study required al-
ternative therapy for their arrhythmia. This included admin-
Figure 3. Programmed ventricular stimulation in a patient with
refractory recurrent ventricular tachycardia. Upperpanel, Control
electrophysiologic study showing induction of sustained ventric-
ular tachycardia (VT). Lower panel,After chronic lorcainide ther-
apy there is suppression of sustained ventricular tachycardia in-
duction, but five repetitive ventricular responses are noted. SIS,
= basic pacing cycle length; S2,S3,S4 = coupled extrastimuli; CL
= cycle length; EPS = electrophysiologic study; HBE = His
bundle electrogram; NSR = normal sinus rhythm.
CONTROL EPS
istration of mexiletine (one patient) or amiodarone (six pa-
tients) and endocardial resection (two patients).
Adverse effects. Sleep disturbances, most commonly
insomnia, were noted in five patients receiving oral lor-
cainide. Three of these patients also reported vivid dreams,
and two patients with this side effect withdrew from the
study, one after 36 hours and another after 7 days of drug
administration. One patient developed marked confusion
while on lorcainide therapy, which resolved after reduction
in drug dosage.
Discussion
Electrophysiologic effects. Lorcainide is classified as a
type I antiarrhythmic agent on the basis of its cellular elec-
trophysiologic effects. It decreases the rate of rise of the
action potential (Vmax) , reduces conduction velocity and
prolongs the refractory period in a variety of animal tissues
(9). It has no effect on slow channel-mediated electrical
activity. In human studies (l ,10), intravenous lorcainide (2
mg/kg) reduced sinus cycle length, had no effect on intra-
atrial conduction and prolonged His-Purkinje and intraven-
tricular conduction. Intravenous lorcainide also increased
correctedsinus node recovery time, had no consistenteffect
on atrial effective refractory period, but mayor may not
have prolonged ventricular effective refractory period (l, 10).
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Figure 4. Plasma concentrations of lorcainide and nor-lorcainide
at follow-up electrophysiologic study (EPS). Brackets indicate
range of values during chronic oral lorcainide therapy reported in
other studies.
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ventricular tachycardia in five patients with drug refractory
ventricular tachycardia. These differences are probably re-
lated to patient selection in these studies, with more re-
fractory arrhythmias in the latter study.
In our study, oral lorcainide suppressed electrically in-
duced ventricular tachycardia in 4 of II patients with re-
fractory ventricular tachycardia. Oral administration results
in substantially greater effects on ventricular refractoriness
and this could explain the response in this patient group. It
could also be explained by inability to attain sufficiently
premature coupling intervals after lorcainide to initiate ven-
tricular tachycardia. Drug concentrations for both lorcainide
and nor-Iorcainide at the time of electrophysiologic study
were in the therapeutic range reported for chronic oral ther-
apy in other studies. However, the efficacy rate in refractory
ventricular tachycardia was certainly not striking, and ad-
verse effects resulted in further attrition in the number of
patients able to continue long-term drug therapy.
Adverse effects were frequent and difficult to manage.
We therefore conclude that chronic lorcainide therapy may
be effective in some patients with refractory ventricular
tachycardia, but continued long-term therapy is severely
limited by its adverse effects.
Ventriculoatrial conduction was abolished (O'Keefe DB,
unpublished observations).
In our study, oral lorcainide did prolong atrioventricular
and intraventricular conduction and ventricular repolariza-
tion. In contrast to intravenous administration, chronic oral
administration does not alter sinus cycle length and signif-
icantly prolongs ventricular effective refractory period. Oral
effects may be due to accumulation either of the parent
compound at the tissue level or of the active metabolite,
nor-Iorcainide alone, or a combination of both effects. Nor-
lorcainide has been reported to have electrophysiologic ef-
fects comparable with those of the parent compound (II).
Antiarrhythmic effects. Intravenous and orallorcainide
have been efficacious in suppression of ventricular prema-
ture depolarizations in uncontrolled and controlled studies
(2-4, 12). The efficacy of lorcainide in patients with re-
current ventricular tachycardia is unclear. Cocco and Strozzi
(13) reported suppression of ventricular tachycardia in six
of seven patients with recurrent ventricular tachycardia or
fibrillation with oral doses of 200 to 300 mg/day. Somani
and di Giorgi (2) reported a similar result in a single patient.
Studies (5,6) on the efficacy of intravenous lorcainide in
suppression of induced ventricular tachycardia using pro-
grammed electrical stimulation have been in apparent con-
flict. Somberg et al. (5) found intravenous lorcainide to be
more effective than intravenous lidocaine and comparable
with intravenous procainamide in suppression of electrically
induced ventricular tachycardia. However, Sung and So-
mani (6) did not report any success in suppression of induced
Wc express our appreciation to Ruth Hamson for her excellent assistance
m the preparation of this manuscnpt.
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